Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Bruno Oesch | M | - |
Malcisbo AG
 Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | 14 years |
| Benedikt Weibel | M | 77 |
University of Bern
| 17 years |
| Hansjörg Riedwyl | M | - |
University of Bern
| - |
| Norbert Thom | M | 78 |
University of Bern
| - |
| Tomislav Radjenovic | M | - |
University of Bern
| - |
| Thomas Wiedmer | M | 61 |
University of Bern
| 23 years |
| Robert E. Leu | M | 78 |
University of Bern
| - |
| Ulrich Kihm | M | - |
University of Bern
| 38 years |
| Beat Brechbühl | M | - |
University of Bern
| - |
| Christoph Scharf | M | - |
University of Bern
| - |
| Armin Brun | M | - |
University of Bern
| - |
| Isabelle Romy | M | 59 |
University of Bern
| - |
| Marc Bär | M | - |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | - |
| David Gerber | M | - |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | - |
| Alois B. Lang | M | 73 |
University of Bern
| - |
| Klaus Neftel | M | 79 |
University of Bern
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Markus Aebi | M | - |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | - |
| Lino Camponovo | M | - |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | - |
| Karin Ilg | M | - |
Malcisbo AG
Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 19 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Irene Schiller
- Personal Network
